Manifold raises $18 million Series B to define vertical AI for life sciences and accelerate life-changing medicines to patients. The new funding cements Manifold's leadership in the $2 trillion life sciences market, powering next-generation AI workflows from early discovery through precision care. Newton, MA (December 18, 2025) - Manifold, the AI platform for life sciences, today announced an $18 million Series B funding round led by Reach Capital, with participation from SilverArc Capital, Industry Ventures, and existing investors TQ Ventures and Calibrate Ventures. The round brings Manifold's total capital raised to $40 million and positions the company as the emerging category leader in vertical AI for life sciences. Manifold's platform is transforming how biopharma companies and medical centers accelerate workflows from target identification to clinical development, market access, and precision medicine in the clinic. Defining vertical AI for life sciences. Vertical AI platforms are transforming productivity in major industries - legal services, financial services, customer experience, and more - with support for domain-specific data, workflows, and governance that go much deeper than horizontal platforms. In life sciences, a $2 trillion industry where productivity directly impacts patient outcomes, Manifold is defining this category. This field requires purpose-built infrastructure for multi-entity collaboration, multimodal biomedical data, and workflows that span from bench to clinic. Manifold's platform is purpose-built for this complexity. "In every industry, companies that combine agentic AI and domain-specific context will transform productivity. Customers are seeking proven partners in this transformation. We believe Manifold is the emerging category leader for vertical AI in life sciences," said Jennifer Carolan, Partner at Reach Capital. Accelerating Agent development and the data flywheel. The new funding will enable Manifold to advance its platform with capabilities that materially improve life sciences productivity: * Expand the Agent OS: Advancing how AI agents operate on multimodal biomedical data, use scientific tools, and leverage institutional context to accelerate work, from biomarker development and model validation through trial design and real-world evidence generation. * Deepen collaboration infrastructure: Extending features that enable teams to share analyses, reuse context, and work across organizational boundaries with appropriate governance and data sovereignty. * Scale the data ecosystem: Constructing novel datasets becomes easier as more organizations join, compounding value for all participants while maintaining data ownership and governance. Strategic milestones and growing momentum. Over the past year, Manifold has achieved significant milestones that demonstrate both strong product-market fit and compounding network effects: * Workflow breadth: AI agents which can be tailored to specific datasets and tools across dozens of workflows - from cohort identification and biomarker discovery to treatment pathway analysis and outcomes research. * Enterprise momentum: A growing customer base including leading companies like Foundation Medicine and academic centers like the University of Virginia. * Strategic collaborations: Deepening strategic collaborations with the Broad Institute, AWS, and Anthropic which strengthen both scientific and technical capabilities and go-to-market reach. * Terra operation: As an operator of Terra, Manifold now serves thousands of researchers across hundreds of life sciences organizations globally. "Our customers and partners are pushing the boundaries of what's possible in life sciences, and we're honored to build alongside them. This funding accelerates our shared goal to transform productivity in life sciences and get life-changing medicines to patients faster," said Vinay Seth Mohta, CEO, Manifold. For an inside look at the vision driving Manifold's next phase of growth, visit the CEO blog. About Manifold. Manifold is the AI platform for life sciences, accelerating life-changing medicines to patients. Its products speed up workflows in areas from target identification and clinical development to market access and precision medicine in the clinic, while maintaining the governance life sciences requires. Global companies and premier research institutions use Manifold to operate faster and more effectively. Backed by leading investors including Reach Capital, TQ Ventures, Calibrate Ventures, SilverArc Capital, and Industry Ventures, Manifold serves tens of thousands of users across hundreds of organizations globally.

What You Should Know:– The Broad Institute of MIT and Harvard is collaborating with Manifold, a leader in AI-powered research infrastructure, to develop a next-generation platform for biomedical research.– The strategic partnership aims to enhance data analysis, secure sharing, and global collaboration, empowering scientists worldwide to accelerate discovery.Manifold: Accelerating Biomedical Research with AIFounded in 2016, Manifold’s AI-powered platform streamlines biomedical research by automating manual tasks in data collection, organization, governance, and analysis. This allows researchers to focus on scientific discovery, unlocking the full potential of their data without technical barriers.Building on the success of Terra, a trusted platform for large-scale data analysis, the new platform will address the evolving needs of modern life sciences research. It will incorporate advanced capabilities while upholding Terra’s core values of secure sharing, global collaboration, and responsible data stewardship.Enhanced Capabilities for a New Era of ResearchThe new platform will introduce several key enhancements:Bring Your Own Cloud: Offers flexibility for researchers to work within their organization’s cloud strategy.Offers flexibility for researchers to work within their organization’s cloud strategy. Enhanced Scalability: Accommodates the growing volume and complexity of biomedical data.Accommodates the growing volume and complexity of biomedical data. Data Harmonization: Seamlessly integrates diverse datasets while ensuring data ownership and control.Seamlessly integrates diverse datasets while ensuring data ownership and control. Purpose-Built AI Agents: Provides advanced capabilities like natural language search, cohort building, and automated analysis.Provides advanced capabilities like natural language search, cohort building, and automated analysis

Morehouse School of Medicine Tackles Cancer Disparities with AI-Driven Research. by Syed Hamza Sohail 09/20/2024 Leave a Comment. What You Should Know:– Manifold, an AI-powered clinical data platform, announced that Morehouse School of Medicine (MSM) will leverage their platform to modernize cancer genomics data analysis and improve collaboration among multidisciplinary stakeholders.– With Manifold, the Institute of Translational Genomic Medicine (ITGM) at MSM is building a modern data foundation to accelerate cancer research—integrating multimodal sources like clinical outcomes, genomics, survey, and geospatial data, making them accessible for exploration by researchers with a wide range of coding experience.Enhancing Breast Cancer Research with AI-Driven Data Integration in Underrepresented PopulationsAs healthcare data continues to grow in volume and complexity, legacy technologies struggle to accommodate the diverse range of data modalities, such as digital pathology slides and unstructured medical notes. These outdated tools lack the necessary capabilities to support advanced analytical techniques like machine learning. Manifold’s cutting-edge technology will empower MSM with AI-powered data analysis, enabling the integration of varied data types into a cohesive platform, thereby unlocking previously inaccessible insights.The initial focus of Dr. Davis and the research team will be advancing breast cancer research among African ancestry patients enrolled in the Polyethnic 1000 study at the New York Genome Center